新型磷结合剂的研究进展  

Research progress on new phosphate binders

作　　者：刘永贵[1] 于鹏[1] 吴疆[1] 沈雪砚[1] 陈常青[1] 

机构地区：[1]天津药物研究院,天津300193

出　　处：《现代药物与临床》2014年第2期201-205,共5页Drugs & Clinic

摘　　要：慢性肾脏病(CKD)患者肾功能减退,引发钙磷的代谢紊乱,进一步导致各种疾病的发生。高磷血症可能会升高CKD患者的发病率和死亡率。因而,有效控制血清磷的水平将是CKD患者预后的关键。传统磷结合剂常含钙、铝成分,虽能有效降低血清磷,但不良反应较多。综述上市的和临床研究中的新型磷结合剂如司维拉姆、碳酸镧、考来替兰和柠檬酸铁等,其不含钙、铝,能有效控制血清磷水平,却不升高血钙,为控制高磷血症和减少血管钙化风险提供了治疗前景。Chronic kidney disease （CKD） can make kidney function worsen, which causes the metabolic disorders of calcium and phosphorus, and timber lead to various diseases. Hyperphosphatemia may elevate the morbidity and mortality of CKD patients. Therefore, it is important to effectively control serum phosphorus level for CKD patients. The traditional phosphate binders mostly contain calcium and aluminum, which can effectively reduce serum phosphorus, but have more adverse reactions. New phosphate binders, such as sevelamer, lanthanum carbonate, colestilan, ferric citrate, etc, can effectively control serum phosphorus level without elevating blood calcium level, which provides a new future in controlling hyperphosphatemia and not raising the risk of vascular calcification.

关 键 词：高磷血症 磷结合剂 司维拉姆 碳酸镧 考来替兰 柠檬酸铁 

分 类 号：R983[医药卫生—药品]